Yale researchers led by Raghav Sehgal and Albert Higgins-Chen analyzed findings from 51 clinical studies to identify which anti-aging treatments produce measurable changes in biological age, as reported in Nature Medicine.
The team examined over 110 DNA methylation biomarkers, including 16 epigenetic clocks that measure chemical patterns attached to DNA. These patterns shift as people age, and some treatments may reverse age-associated changes.
The strongest reductions in biological age markers came from prescription medications. Metformin and semaglutide, used to manage metabolic conditions and body weight, showed the clearest results. Anti-TNF therapies that target inflammatory proteins also produced measurable improvements.
Combining diet and exercise consistently reduced epigenetic age across multiple dietary approaches tested, including Mediterranean, low-fat, and low-carb diets.
Over-the-counter supplements and some medical procedures showed little evidence of producing measurable reductions in biological age.
Sehgal noted that the research provides a new way to evaluate anti-aging treatments. "For the first time we've shown that certain therapies have measurable impacts," he said. "This wasn't previously possible, because we didn't have enough data to say these biomarkers are consistently responsive to these interventions."
Higgins-Chen cautioned about interpreting the findings. "We have developed a rigorous, systematic approach to evaluating and comparing how biomarkers change across a wide variety of interventions, and that is a critical step in the right direction," he said. "However, the true meaning of that change must be fully understood."
The researchers emphasized that changes in biological age markers do not necessarily mean people will live longer or avoid age-related diseases. Key questions remain about whether changes are directly caused by treatments and whether improvements in epigenetic age translate to meaningful long-term health benefits.